EMAIL THIS PAGE TO A FRIEND

Drug metabolism and disposition: the biological fate of chemicals

A recombinant humanized anti-cocaine monoclonal antibody inhibits the distribution of cocaine to the brain in rats.


PMID 24733787

Abstract

The monoclonal antibody (mAb), h2E2, is a humanized version of the chimeric human/murine anti-cocaine mAb 2E2. The recombinant h2E2 protein was produced in vitro from a transfected mammalian cell line and retained high affinity (4 nM Kd) and specificity for cocaine over its inactive metabolites benzoylecgonine (BE) and ecgonine methyl ester. In rats, pharmacokinetic studies of h2E2 (120 mg/kg i.v.) showed a long terminal elimination half-life of 9.0 days and a low volume of distribution at steady state (Vdss) of 0.3 l/kg. Pretreatment with h2E2 produced a dramatic 8.8-fold increase in the area under the plasma cocaine concentration-time curve (AUC) and in brain a concomitant decrease of 68% of cocaine's AUC following an i.v. injection of an equimolar cocaine dose. Sequestration of cocaine in plasma by h2E2, shown via reduction of cocaine's Vdss, indicates potential clinical efficacy. Although the binding of cocaine to h2E2 in plasma should inhibit distribution and metabolism, the elimination of cocaine remained multicompartmental and was still rapidly eliminated from plasma despite the presence of h2E2. BE was the major cocaine metabolite, and brain BE concentrations were sixfold higher than in plasma, indicating that cocaine is normally metabolized in the brain. In the presence of h2E2, brain BE concentrations were decreased and plasma BE was increased, consistent with the observed h2E2-induced changes in cocaine disposition. The inhibition of cocaine distribution to the brain confirms the humanized mAb, h2E2, as a lead candidate for development as an immunotherapy for cocaine abuse.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

95541
Chlorotrimethylsilane, produced by Wacker Chemie AG, Burghausen, Germany, ≥99.0% (GC)
C3H9ClSi
92361
Chlorotrimethylsilane, ≥98.0% (GC)
C3H9ClSi
92360
Chlorotrimethylsilane, puriss., ≥99.0% (GC)
C3H9ClSi
89595
Chlorotrimethylsilane, for GC derivatization, ≥99.0% (GC)
C3H9ClSi
385433
Chlorotrimethylsilane solution, 1.0 M in methylene chloride
C3H9ClSi
384410
Chlorotrimethylsilane solution, 1.0 M in THF
C3H9ClSi
368407
Deuterium, 99.96 atom % D
D2
617474
Deuterium, 99.9 atom % D
D2
361860
Deuterium, 99.8 atom % D
D2
488690
Deuterium hydride, extent of labeling: 96 mol% DH, 98 atom % D
HD
15222
N,O-Bis(trimethylsilyl)trifluoroacetamide, for GC derivatization, ≥99.0%
C8H18F3NOSi2
155195
N,O-Bis(trimethylsilyl)trifluoroacetamide, ≥99%
C8H18F3NOSi2
394653
N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane, with 10% trimethylchlorosilane, for GC derivatization, ≥98.0%
C8H18F3NOSi2
T6381
N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane, with 1% trimethylchlorosilane, for GC derivatization
C8H18F3NOSi2
15238
N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane, for GC derivatization, contains 1% TMCS, 99% (excluding TMCS)
C8H18F3NOSi2
15209
N,O-Bis(trimethylsilyl)trifluoroacetamide with trimethylchlorosilane, for GC derivatization, contains 10% TMCS, 98% (excluding TMCS)
C8H18F3NOSi2